[go: up one dir, main page]

WO2009038012A1 - Heterocyclic compound - Google Patents

Heterocyclic compound Download PDF

Info

Publication number
WO2009038012A1
WO2009038012A1 PCT/JP2008/066400 JP2008066400W WO2009038012A1 WO 2009038012 A1 WO2009038012 A1 WO 2009038012A1 JP 2008066400 W JP2008066400 W JP 2008066400W WO 2009038012 A1 WO2009038012 A1 WO 2009038012A1
Authority
WO
WIPO (PCT)
Prior art keywords
heterocyclic compound
pharmaceutically acceptable
acceptable salt
disease
hyperalgesia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/066400
Other languages
French (fr)
Japanese (ja)
Inventor
Toshio Nakamura
Shuji Saito
Mitsukane Yoshinaga
Hiroshi Ohta
Madoka Kawamura
Tomoko Ishizaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of WO2009038012A1 publication Critical patent/WO2009038012A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A novel heterocyclic compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical preparation comprising the compound or the pharmaceutically acceptable salt as an active ingredient has a potent agonistic activity on an NPFF2 receptor, and is therefore useful for the prevention or treatment of a disease such as a pain, hyperalgesia, eating disorder, obesity, diabetes or a cardiovascular disease.
PCT/JP2008/066400 2007-09-18 2008-09-11 Heterocyclic compound Ceased WO2009038012A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007241502 2007-09-18
JP2007-241502 2007-09-18

Publications (1)

Publication Number Publication Date
WO2009038012A1 true WO2009038012A1 (en) 2009-03-26

Family

ID=40467829

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/066400 Ceased WO2009038012A1 (en) 2007-09-18 2008-09-11 Heterocyclic compound

Country Status (1)

Country Link
WO (1) WO2009038012A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130002991A (en) * 2010-02-08 2013-01-08 엠에스데 오쓰 베.베. 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2018152134A1 (en) * 2017-02-14 2018-08-23 Research Triangle Institute Proline-based neuropeptide ff receptor modulators

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62135473A (en) * 1985-12-06 1987-06-18 Fujisawa Pharmaceut Co Ltd Condensed heterocyclic imidazole compound
WO2004058755A2 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of imidazo[1,5-a]pyridin-3-yl derivatives and related heterobicycles for targetting compounds capable of binding to g-protein coupled receptors
JP2007504220A (en) * 2003-09-03 2007-03-01 ガラパゴス・エヌブイ Imidazo [1,5-a] pyridine or imidazo [1,5-a] piperidine derivatives and their use for the manufacture of a medicament against 5HT2A receptor related disorders
JP2007509060A (en) * 2003-10-15 2007-04-12 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Imidazopyrazine tyrosine kinase inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62135473A (en) * 1985-12-06 1987-06-18 Fujisawa Pharmaceut Co Ltd Condensed heterocyclic imidazole compound
WO2004058755A2 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of imidazo[1,5-a]pyridin-3-yl derivatives and related heterobicycles for targetting compounds capable of binding to g-protein coupled receptors
JP2007504220A (en) * 2003-09-03 2007-03-01 ガラパゴス・エヌブイ Imidazo [1,5-a] pyridine or imidazo [1,5-a] piperidine derivatives and their use for the manufacture of a medicament against 5HT2A receptor related disorders
JP2007509060A (en) * 2003-10-15 2007-04-12 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Imidazopyrazine tyrosine kinase inhibitor

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130002991A (en) * 2010-02-08 2013-01-08 엠에스데 오쓰 베.베. 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
KR101661383B1 (en) 2010-02-08 2016-09-29 머크 샤프 앤 도메 비.브이. 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2018152134A1 (en) * 2017-02-14 2018-08-23 Research Triangle Institute Proline-based neuropeptide ff receptor modulators
CN110546136A (en) * 2017-02-14 2019-12-06 研究三角协会 Proline-based modulators of neuropeptide FF receptors
EP3583090A1 (en) 2017-02-14 2019-12-25 Research Triangle Institute, International Proline-based neuropeptide ff receptor modulators
EP3583090A4 (en) * 2017-02-14 2020-12-30 Research Triangle Institute, International PROLIN-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS
US11491136B2 (en) 2017-02-14 2022-11-08 Research Triangle Institute Proline-based neuropeptide FF receptor modulators
CN110546136B (en) * 2017-02-14 2023-07-18 研究三角协会 Proline-based neuropeptide FF receptor modulators
US11826350B2 (en) 2017-02-14 2023-11-28 Research Triangle Institute Proline-based neuropeptide FF receptor modulators
US12390446B2 (en) 2017-02-14 2025-08-19 Research Triangle Institute Proline-based neuropeptide FF receptor modulators

Similar Documents

Publication Publication Date Title
WO2010122980A8 (en) NOVEL THYROID HORMONE β RECEPTOR AGONIST
WO2008136392A1 (en) Preparation for oral administration
WO2009051119A1 (en) Pyrimidyl indoline compound
MX2009011276A (en) Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity.
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
WO2010026436A3 (en) 1,3, 4, 6, 7, 11b-hexahydro-benzo[alpha]quinolizines for the treatment of hyperkinetic movement and related disorders
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2005044192A3 (en) Triazole compounds and uses related thereto
ZA200706021B (en) 1-thio-D-glucitol derivatives
WO2007135527A3 (en) Benzimidazolyl compounds
UA94455C2 (en) Oxadiazolidinedione compound
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
ZA200706354B (en) Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2006124447A3 (en) Substituted n-arylpyrrolidines as selective androgen receptor modulators
WO2009004082A3 (en) Anticonvulsive pharmaceutical compositions
WO2004052370A3 (en) Quinoline compounds for use in mch receptor related disorders
WO2008156094A1 (en) Pyridazinone derivative and pde inhibitor containing the same as active ingredient
WO2007065808A3 (en) Neuropeptide-2 receptor-agonists
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
WO2006020959A3 (en) Substituted benzofused heterocycles
WO2011045232A3 (en) Neuropeptide-2 receptor (y-2r) agonists
WO2007105113A3 (en) Use of crf1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08831339

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08831339

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP